Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is facing temporary issues in the form of the recent PFS and OPPS schedule updates, which have impacted two of its four revenue streams but not its Advanced Surgical and international Wound Care segments. The company expects to incur a one-time restructuring charge in 2Q26, but is continuing to perform well and expects to see double-digit top-line growth in the long run. It has a strong track record and a best-in-class suite of clinical data, and is poised to outperform in the new environment with its vertically integrated manufacturing infrastructure and established sales force.

Bears say

MiMedx Group is facing several fundamental risks that could significantly impact its business. These include potential challenges related to tissue donorship, intense competition in the skin substitute market due to strict regulatory restrictions, and the potential termination or expiration of contracts with its major customers. Additionally, the company is facing reimbursement disruptions in the wound care space, resulting in a slow recovery for its Wound Care segment. These factors could lead to a decline in the company's top-line growth and have a negative impact on its financials and stock valuation.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.